CALIFORNIA NANOTECHNOLOGIES (CNO.CA) Stock Fundamental Analysis
Canada - TSX-V:CNO - CA1304921010 - Common Stock
0.345 CAD
-0.05 (-12.66%)
We assign a fundamental rating of 3 out of 10 to CNO. CNO was compared to 22 industry peers in the Machinery industry. The financial health of CNO is average, but there are quite some concerns on its profitability. CNO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CNO had negative earnings in the past year.
CNO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CNO reported negative net income in multiple years.
CNO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CNO has a worse Return On Assets (-21.51%) than 68.18% of its industry peers.
CNO has a Return On Equity of -39.65%. This is in the lower half of the industry: CNO underperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROIC | N/A |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of CNO has grown nicely.
With an excellent Gross Margin value of 69.19%, CNO belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
CNO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CNO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% |
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
2. Health
2.1 Basic Checks
CNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CNO has more shares outstanding than it did 1 year ago.
CNO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CNO is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.63 indicates that CNO is not a great score, but indicates only limited risk for bankruptcy at the moment.
CNO has a better Altman-Z score (2.63) than 68.18% of its industry peers.
The Debt to FCF ratio of CNO is 4.46, which is a neutral value as it means it would take CNO, 4.46 years of fcf income to pay off all of its debts.
CNO's Debt to FCF ratio of 4.46 is fine compared to the rest of the industry. CNO outperforms 77.27% of its industry peers.
CNO has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CNO (0.49) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Altman-Z | 2.63 |
ROIC/WACCN/A
WACC9.43%
2.3 Liquidity
A Current Ratio of 1.19 indicates that CNO should not have too much problems paying its short term obligations.
With a Current ratio value of 1.19, CNO is not doing good in the industry: 77.27% of the companies in the same industry are doing better.
A Quick Ratio of 1.19 indicates that CNO should not have too much problems paying its short term obligations.
CNO has a Quick ratio of 1.19. This is in the better half of the industry: CNO outperforms 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The earnings per share for CNO have decreased strongly by -477.78% in the last year.
CNO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.79%.
CNO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.59% yearly.
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
3.2 Future
Based on estimates for the next years, CNO will show a very strong growth in Earnings Per Share. The EPS will grow by 102.13% on average per year.
Based on estimates for the next years, CNO will show a very negative growth in Revenue. The Revenue will decrease by -11.36% on average per year.
EPS Next Y100%
EPS Next 2Y102.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-42.53%
Revenue Next 2Y-11.35%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CNO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 23.74, the valuation of CNO can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as CNO.
CNO is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 32.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.74 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CNO.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CNO indicates a somewhat cheap valuation: CNO is cheaper than 77.27% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.75 | ||
| EV/EBITDA | 106.45 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CNO's earnings are expected to grow with 102.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y102.13%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CNO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:CNO (11/7/2025, 7:00:00 PM)
0.345
-0.05 (-12.66%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.5%
Ins Owner ChangeN/A
Market Cap16.59M
Revenue(TTM)4.45M
Net Income(TTM)-939.70K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.74 | ||
| P/S | 2.64 | ||
| P/FCF | 35.75 | ||
| P/OCF | 5.63 | ||
| P/B | 4.96 | ||
| P/tB | 4.97 | ||
| EV/EBITDA | 106.45 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY4.21%
FCF(TTM)0.01
FCFY2.8%
OCF(TTM)0.06
OCFY17.76%
SpS0.13
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% | ||
| FCFM | 7.39% |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.86%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Debt/EBITDA | 9.55 | ||
| Cap/Depr | 253.96% | ||
| Cap/Sales | 39.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1711.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.63 |
F-Score5
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)145.85%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
EPS Next Y100%
EPS Next 2Y102.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
Revenue Next Year-42.53%
Revenue Next 2Y-11.35%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.85%
EBIT growth 3Y87.4%
EBIT growth 5Y154.28%
EBIT Next Year-68.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.62%
FCF growth 3Y80.29%
FCF growth 5Y42.36%
OCF growth 1Y667.86%
OCF growth 3Y173%
OCF growth 5Y84.63%
CALIFORNIA NANOTECHNOLOGIES / CNO.CA FAQ
What is the ChartMill fundamental rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CNO.CA.
Can you provide the valuation status for CALIFORNIA NANOTECHNOLOGIES?
ChartMill assigns a valuation rating of 4 / 10 to CALIFORNIA NANOTECHNOLOGIES (CNO.CA). This can be considered as Fairly Valued.
How profitable is CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
CALIFORNIA NANOTECHNOLOGIES (CNO.CA) has a profitability rating of 3 / 10.
What is the financial health of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
The financial health rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) is 4 / 10.